- Home
- PSQH vs IMAB Comparison
PSQH vs IMAB Comparison
Compare PSQH & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSQH
- IMAB
- Stock Information
- Founded
- PSQH 2021
- IMAB 2014
- Country
- PSQH United States
- IMAB United States
- Employees
- PSQH N/A
- IMAB N/A
- Industry
- PSQH Advertising
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PSQH Consumer Discretionary
- IMAB Health Care
- Exchange
- PSQH Nasdaq
- IMAB Nasdaq
- Market Cap
- PSQH 97.5M
- IMAB 200.9M
- IPO Year
- PSQH N/A
- IMAB 2020
- Fundamental
- Price
- PSQH $2.50
- IMAB $2.13
- Analyst Decision
- PSQH Strong Buy
- IMAB Strong Buy
- Analyst Count
- PSQH 2
- IMAB 3
- Target Price
- PSQH $6.00
- IMAB $6.33
- AVG Volume (30 Days)
- PSQH 531.8K
- IMAB 589.5K
- Earning Date
- PSQH 08-13-2025
- IMAB 05-15-2025
- Dividend Yield
- PSQH N/A
- IMAB N/A
- EPS Growth
- PSQH N/A
- IMAB N/A
- EPS
- PSQH N/A
- IMAB N/A
- Revenue
- PSQH $26,483,166.00
- IMAB N/A
- Revenue This Year
- PSQH $85.17
- IMAB N/A
- Revenue Next Year
- PSQH $61.98
- IMAB N/A
- P/E Ratio
- PSQH N/A
- IMAB N/A
- Revenue Growth
- PSQH 201.84
- IMAB N/A
- 52 Week Low
- PSQH $1.63
- IMAB $0.60
- 52 Week High
- PSQH $7.77
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- PSQH 67.39
- IMAB 49.76
- Support Level
- PSQH $2.07
- IMAB $2.06
- Resistance Level
- PSQH $2.63
- IMAB $2.41
- Average True Range (ATR)
- PSQH 0.14
- IMAB 0.33
- MACD
- PSQH 0.05
- IMAB -0.07
- Stochastic Oscillator
- PSQH 90.62
- IMAB 12.63
About PSQH PSQ Holdings Inc.
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).